Physician profile
Alvin Burstein
NPI 1962553412
$18,051.34
in general payments reported to CMS, 2019-2025
35 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,590 · 2020: $728 · 2021: $1,294 · 2022: $2,306 · 2023: $5,921 · 2024: $2,478 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,626 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,090 · Consulting Fee: $350 · Education: $48.84 · Travel and Lodging: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,626.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,090.00 |
| Consulting Fee | $350.00 |
| Education | $48.84 |
| Travel and Lodging | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,783.84 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Allergan, INC. | $2,196.55 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,777.91 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,525.93 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,117.12 | 2019-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Takeda Pharmaceuticals U.S.A., INC. | $945.91 | 2019-2025 | Trintellix |
| Lundbeck LLC | $709.78 | 2019-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $611.44 | 2019-2022 | |
| Alkermes, INC. | $576.93 | 2019-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $520.75 | 2019-2022 | |
| Almatica Pharma LLC | $514.57 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Jazz Pharmaceuticals INC. | $460.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $398.49 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $370.10 | 2021-2025 | Fanapt, Hetlioz |
| Avadel Cns Pharmaceuticals, LLC | $348.94 | 2024-2025 | Lumryz |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Burstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.